Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triweekly Chemotherapy With Bevacizumab Versus Intraperitoneal Chemotherapy as Frontline Therapy in Advanced Ovarian Cancer

NCT05410938 is registered in ClinicalTrials.gov with Far Eastern Memorial Hospital as lead sponsor.

NCT NCT05410938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triweekly Chemotherapy With Bevacizumab Versus Intraperitoneal Chemotherapy as Frontline Therapy in Advanced Ovarian Cancer
Lead sponsor
Far Eastern Memorial Hospital
Phase
Observational
Overall status
Completed
Start date
June 6, 2022
Completion date
May 1, 2023
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intraperitoneal chemotherapy, bevacizumab, ovarian cancer